Liraglutide Featured in New Trial on Pasireotide Hyperglycaemia

A clinical trial involving liraglutide was registered with a status update dated October 8, 2026. The study, titled "Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet," is listed under identifier NCT07866846. The trial is currently in the recruiting phase, meaning it is actively enrolling participants. The phase is listed as not applicable. This study focuses on patients with acromegaly who experience hyperglycaemia associated with pasireotide treatment, and examines the use of a ketogenic diet as part of management. No results have been posted for this trial at this time. The update reflects only the recruitment status and trial details as registered. No efficacy or safety outcomes can be reported until results are made available through official channels. Readers should note that trial status can change and recruitment does not indicate any conclusions about treatment effects. Those interested in following this study can refer to its public listing for updates on progress and eventual outcomes. For more background on liraglutide, including its approved uses and general profile, readers can consult the compound overview.